CheckMate 649 3-Year Follow-up: Nivolumab Plus Chemotherapy for Gastric and Esophageal Cancers
CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC
Checkmate 649 | Out now on Plenary Session Podcast feed
Overview of gastroesophageal cancer
FDA D.I.S.C.O. Burst Edition: FDA approvals of Trodelvy (sacituzumab govitecan) for locally advan...
33 First Line Therapy for HER2- PDL1+ GEA
Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications
Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus and GEJ?
Clinical Trials Updates for Gastric Cancer Patients Webinar
Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care
Immunotherapy Management of Early and Advanced Gastric, Esophageal, GEJ, and Colorectal Cancers
Targeted Treatment Strategies: Innovative Approaches for the Management of Gastric Cancer
Upper Gastrointestinal Cancer | 2022 OneOncology Conference
Advanced Gastroesophageal Cancers: Maximizing the Benefits of Novel Immunotherapy Approaches
Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer
Clinical Trials Updates for Gastric Cancer Patients
Catalysts for Change in Gastric & GEJ Cancer
Gastrointestinal Cancer CME Series: Gastroesophageal Cancer
CheckMate 459: Nivolumab plus chemotherapy for GC / GEJC / EAC
Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer